Recent weeks have seen heightened debate over the need for phase 3 confirmatory trials for biosimilars, with some stakeholders calling these trials unnecessary and others going so far as to call them unethical. During the SMi 9th annual conference on Biosimilars and Biobetters, held September 26-27 in London, United Kingdom, Uwe Gudat, MD, who serves as head of clinical safety and pharmacovigilance at Fresenius Kabi, weighed in. “The subject I raise is rather provocative,” he acknowledged.
Recent weeks have seen heightened debate over the need for phase 3 confirmatory trials for biosimilars, with some stakeholders calling these trials unnecessary and others going so far as to call them unethical.
During the SMi 9th annual conference on Biosimilars and Biobetters, held September 26-27 in London, United Kingdom, Uwe Gudat, MD, who serves as head of clinical safety and pharmacovigilance at Fresenius Kabi, weighed in. “The subject I raise is rather provocative,” he acknowledged, adding that he was expressing personal views that may not align with those of his organization.
The classical approach to product development, said Gudat, is “a pretty complex affair, and you’ve got a lot of questions to answer,” but the same is not necessarily true of biosimilars, where the goal of clinical trials is to address residual uncertainty. “We use the same tools” as innovator developers, he said, “with different objectives.”
Read more about the controversy over phase 3 clinical trials for biosimilars.
Given advances in analytical methods for understanding the structure—function relationship of biologic medicines, developers now have less residual uncertainty concerning their molecules. “Once I know what I’ve got, I pretty well know what it does,” he said. Given this fact, “Why bother with clinical studies? Why are we doing this?”
Said Gudat, “There’s a backroad that we sometimes forget. The clinic informs what type of analytical characterization is underlying, which informs of the structure [of the molecule]. The human body is a catch-all assay,” he added, that can potentially find a rupture in the analytical characterization of the biosimilar.
However, despite the fact that the clinical trial is being used as a safety net for potential errors, approaches to conducting these trials are remarkably variable. Biosimilars of rituximab, for example, are being tested in a wide variety of indications with small sample sizes in each indication. “There seems to be no single answer to the clinical study question” in terms of study population, despite the need to test these products in the most sensitive population. “There’s confusion in the space,” said Gudat. Furthermore, given that large sample sizes would likely be necessary to truly reduce residual uncertainty about a molecule, and given that clinical trials carry an inherent risk for patients, further consideration about the need for these trials may be warranted.
Gudat also noted that the current EU clinical trials directive holds that repetitive tests should not be carried out; this fact raises the question of whether repeatedly characterizing the safety profile of a drug in healthy volunteers in order to facilitate biosimilar studies is merely generating evidence that is already known, as well as the question of whether the practice contradicts the directive.
However, Gudat did not go so far as to say that clinical trials for these products should become a thing of the past. Instead, in his view, they may warrant rethinking. In undertaking clinical trials, he said, developers may be underutilizing biodynamic markers as a way to address residual uncertainty.
Pharmacodynamic (PD) markers, he explained, have been developed and used as stand-ins for clinical endpoints, and according to the FDA, use of an established PD marker can be used to add to the overall demonstration of biosimilarity. Using a broader panel of biomarkers, said Gudat, could have value.
In closing his talk, Gudat noted that “do we still need clinical trials for biosimilars?” may be the wrong question altogether. Instead, he proposed, “do we need to approach clinical development of a biosimilar with a completely different mindset?” may be the more important question.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.